The financials
Iovance Biotherapeutics, Inc. by the numbers
Iovance Biotherapeutics, Inc. (IOVA) reported revenue of $71M in Q1 2026 (quarter ended March 31, 2026), up 45% from the same quarter a year earlier. That came with a gross margin of 41% and net loss of $79M. For the full year FY2025, revenue was $264M (+61% year on year) and net income −$391M. Its largest product in 2026-Q1 was Amtagvi at $60M, 84% of the disclosed total, just ahead of Proleukin at 16%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $71M | $49M | +45% |
| Gross profit | $29M | $6.6M | +338% |
| Operating income | −$81M | −$121M | n/a |
| Net income | −$79M | −$116M | n/a |
| Diluted EPS | −$0.19 | −$0.36 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Amtagvi | $60M | 84% |
| Proleukin | $11M | 16% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $71.4M (+5.9%)
Proleukin grew +95% year on yearAmtagvi +38% year on year
Segment Latestquarter on quarteryear on year
- Amtagvi$60.2M$60.2MQoQ +4.8%year on year +38%+4.8%+38%
- Proleukin$11.2M$11.2MQoQ +12%year on year +95%+12%+95%